Flucloxacillin Dosing for Adults
For methicillin-susceptible Staphylococcus aureus (MSSA) skin and soft tissue infections, the standard adult dose is 500 mg four times daily (QID) orally or 1-2 g every 4-6 hours intravenously, though emerging evidence suggests these standard doses may be insufficient for critically ill patients or serious infections.
Standard Dosing Regimens
Oral Administration
- Mild to moderate MSSA infections: 500 mg QID (four times daily) 1
- Alternative: Dicloxacillin 500 mg QID 1
Intravenous Administration
Critical Considerations for Dosing Optimization
For Critically Ill Patients
The standard dosing recommendations above are increasingly recognized as inadequate for critically ill patients. Recent pharmacokinetic studies demonstrate that standard doses of 8-12 g/24h may result in subtherapeutic unbound concentrations in up to 74% of critically ill patients 2.
Key dosing adjustments for severe infections:
- Continuous infusion of 12 g/24h achieves target attainment in only 26% of critically ill patients for MIC of 2 mg/L 2
- Continuous infusion of 24 g/24h may be required for adequate target attainment (51% success rate) 2
- For aggressive PK/PD targets (100% fT>4-5×MIC), continuous infusion of 12 g/24h or higher is recommended 3
Continuous Infusion Strategy
For serious MSSA infections (endocarditis, osteomyelitis, deep abscess), continuous infusion is superior to intermittent dosing:
- 8-12 g/24h by continuous infusion maintains serum concentrations of 8-40 mg/L, well above typical MICs 4
- Achieves 82% clinical cure rate in serious staphylococcal sepsis 4
- Better suited for home-based parenteral therapy 4
Renal Impairment Dosing
Patients with impaired renal function require substantial dose reduction to avoid toxicity:
- eGFR <50 mL/min/1.73m²: High risk of supratherapeutic concentrations 5
- During renal replacement therapy (CVVH): Start with 4 g/24h and adjust based on therapeutic drug monitoring 6
- Threshold for nephrotoxicity: Unbound concentration >10 mg/L (66.7% develop nephrotoxicity above this level) 5
- Threshold for neurotoxicity: Unbound concentration >21 mg/L (46.2% develop neurotoxicity above this level) 5
Therapeutic Drug Monitoring (TDM)
TDM of unbound flucloxacillin is strongly recommended for:
- Critically ill patients 2, 7
- Patients with eGFR <50 mL/min/1.73m² 5
- High daily doses (>8 g/24h) 5
- Serious infections requiring aggressive targets 3
Target concentrations:
- Minimum target: Unbound concentration 4-10× MIC (typically 1-2.5 mg/L for MIC 0.25-0.5 mg/L) 5
- For serious infections: Maintain unbound concentration >2.5 mg/L (100% fT>5×MIC) 7
Important Clinical Pitfalls
Protein Binding Variability
Flucloxacillin is highly protein-bound (95-97% in healthy individuals), but critically ill patients demonstrate dramatically higher unbound fractions (7-72%) due to hypoalbuminemia 7. This means:
- Total drug concentrations are misleading
- Unbound concentrations should guide dosing decisions
- Standard doses may paradoxically lead to both underdosing (insufficient total drug) and toxicity (excessive unbound drug in renal failure)
Drug-Drug Interactions
Flucloxacillin induces CYP450 enzymes, UGT enzymes, and P-glycoprotein, leading to decreased exposure of concomitant medications with narrow therapeutic windows 8. Monitor closely when combining with:
- Immunosuppressants
- Anticoagulants
- Antiepileptics
Tolerability Considerations
Cefazolin may be better tolerated than flucloxacillin for MSSA bloodstream infections, with significantly fewer adverse events leading to discontinuation (0% vs 13%) 9. Consider cefazolin 1 g every 8 hours IV as an alternative first-line agent 1.
Practical Dosing Algorithm
- Mild-moderate outpatient SSTI: 500 mg PO QID
- Hospitalized non-ICU patient with MSSA: 1-2 g IV every 4-6 hours
- Critically ill patient: Start 12 g/24h continuous infusion, consider increasing to 24 g/24h based on TDM
- Serious infection (endocarditis, osteomyelitis): 8-12 g/24h continuous infusion with TDM
- eGFR <50 mL/min: Reduce dose by 50% and implement mandatory TDM
- Renal replacement therapy: Start 4 g/24h with TDM-guided adjustment